Dr. Hönle AG Logo

Dr. Hönle AG

HNL.DE

(0.8)
Stock Price

9,00 EUR

-3.6% ROA

-5.71% ROE

-13.05x PER

Market Cap.

70.014.414,00 EUR

57.74% DER

0% Yield

-5.44% NPM

Dr. Hönle AG Stock Analysis

Dr. Hönle AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dr. Hönle AG Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.1x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

2 DER

The stock has a reasonable amount of debt compared to its ownership (57%), suggesting a balanced financial position and a moderate level of risk.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-23.2%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-15.98%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-106) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Dr. Hönle AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dr. Hönle AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Dr. Hönle AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dr. Hönle AG Revenue
Year Revenue Growth
2002 13.285.000
2003 17.723.000 25.04%
2004 22.418.000 20.94%
2005 22.822.000 1.77%
2006 0 0%
2007 26.246.000 100%
2008 48.744.000 46.16%
2009 44.985.000 -8.36%
2010 54.624.000 17.65%
2011 67.878.000 19.53%
2012 72.092.000 5.85%
2013 77.273.000 6.7%
2014 82.090.000 5.87%
2015 92.173.000 10.94%
2016 93.415.000 1.33%
2017 101.926.000 8.35%
2018 126.492.000 19.42%
2019 107.747.000 -17.4%
2020 93.876.000 -14.78%
2021 115.170.000 18.49%
2022 126.529.000 8.98%
2023 104.880.000 -20.64%
2023 106.342.000 1.37%
2024 95.788.000 -11.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dr. Hönle AG Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1.034.000 100%
2013 1.138.000 9.14%
2014 3.877.000 70.65%
2015 4.107.999 5.62%
2016 4.377.000 6.15%
2017 4.844.000 9.64%
2018 5.610.000 13.65%
2019 6.087.000 7.84%
2020 5.969.000 -1.98%
2021 6.518.000 8.42%
2022 7.154.000 8.89%
2023 0 0%
2023 7.539.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dr. Hönle AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 5.612.000
2003 5.686.000 1.3%
2004 6.509.000 12.64%
2005 6.837.000 4.8%
2006 0 0%
2007 7.576.000 100%
2008 13.922.000 45.58%
2009 0 0%
2010 5.034.000 100%
2011 5.561.000 9.48%
2012 2.436.000 -128.28%
2013 2.498.000 2.48%
2014 2.173.000 -14.96%
2015 1.677.000 -29.58%
2016 2.157.000 22.25%
2017 1.743.000 -23.75%
2018 1.664.000 -4.75%
2019 1.765.000 5.72%
2020 2.504.000 29.51%
2021 2.568.000 2.49%
2022 2.984.000 13.94%
2023 0 0%
2023 2.720.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dr. Hönle AG EBITDA
Year EBITDA Growth
2002 -977.000
2003 2.377.000 141.1%
2004 3.346.000 28.96%
2005 4.021.000 16.79%
2006 10.191.000 60.54%
2007 11.058.000 7.84%
2008 7.207.000 -53.43%
2009 -2.667.000 370.23%
2010 6.766.000 139.42%
2011 12.819.000 47.22%
2012 10.709.000 -19.7%
2013 11.655.000 8.12%
2014 12.108.000 3.74%
2015 16.667.000 27.35%
2016 15.115.000 -10.27%
2017 18.216.000 17.02%
2018 33.939.000 46.33%
2019 20.763.000 -63.46%
2020 15.335.000 -35.4%
2021 13.909.000 -10.25%
2022 2.825.000 -392.35%
2023 -36.228.000 107.8%
2023 1.502.000 2511.98%
2024 5.272.000 71.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dr. Hönle AG Gross Profit
Year Gross Profit Growth
2002 7.790.000
2003 11.470.000 32.08%
2004 13.471.000 14.85%
2005 14.163.000 4.89%
2006 8.253.000 -71.61%
2007 35.128.000 76.51%
2008 25.944.000 -35.4%
2009 23.669.000 -9.61%
2010 32.215.000 26.53%
2011 39.888.000 19.24%
2012 45.538.000 12.41%
2013 48.432.000 5.98%
2014 52.554.000 7.84%
2015 58.999.000 10.92%
2016 59.853.000 1.43%
2017 65.799.000 9.04%
2018 85.400.000 22.95%
2019 72.824.000 -17.27%
2020 60.537.000 -20.3%
2021 69.343.000 12.7%
2022 62.286.000 -11.33%
2023 19.600.000 -217.79%
2023 53.347.000 63.26%
2024 13.904.000 -283.68%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dr. Hönle AG Net Profit
Year Net Profit Growth
2002 -1.278.000
2003 2.064.000 161.92%
2004 2.205.000 6.39%
2005 2.708.000 18.57%
2006 0 0%
2007 3.167.000 100%
2008 4.569.000 30.69%
2009 -4.083.000 211.9%
2010 4.806.000 184.96%
2011 6.879.000 30.14%
2012 5.848.000 -17.63%
2013 6.620.000 11.66%
2014 6.256.000 -5.82%
2015 10.128.000 38.23%
2016 8.278.000 -22.35%
2017 10.427.000 20.61%
2018 21.738.000 52.03%
2019 12.477.000 -74.22%
2020 5.678.000 -119.74%
2021 -4.860.000 216.83%
2022 -13.198.000 63.18%
2023 -36.892.000 64.23%
2023 -11.006.000 -235.2%
2024 -1.060.000 -938.3%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dr. Hönle AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 0 0%
2004 0 0%
2005 1 0%
2006 0 0%
2007 1 0%
2008 1 0%
2009 -1 0%
2010 1 0%
2011 1 100%
2012 1 0%
2013 1 0%
2014 1 0%
2015 2 0%
2016 2 0%
2017 2 0%
2018 4 66.67%
2019 2 -50%
2020 1 -100%
2021 -1 0%
2022 -2 100%
2023 -6 66.67%
2023 -2 -500%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dr. Hönle AG Free Cashflow
Year Free Cashflow Growth
2002 -3.648.000
2003 231.000 1679.22%
2004 1.393.000 83.42%
2005 -91.000 1630.77%
2006 4.326.000 102.1%
2007 5.275.000 17.99%
2008 1.043.000 -405.75%
2009 -4.473.000 123.32%
2010 3.777.000 218.43%
2011 8.710.000 56.64%
2012 1.392.000 -525.72%
2013 2.704.000 48.52%
2014 4.407.000 38.64%
2015 7.023.000 37.25%
2016 3.376.000 -108.03%
2017 1.218.000 -177.18%
2018 13.639.000 91.07%
2019 -2.354.000 679.4%
2020 -22.963.000 89.75%
2021 -15.959.000 -43.89%
2022 -11.715.000 -36.23%
2023 209.000 5705.26%
2023 317.000 34.07%
2024 -132.000 340.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dr. Hönle AG Operating Cashflow
Year Operating Cashflow Growth
2002 -1.954.000
2003 1.001.000 295.2%
2004 1.748.000 42.73%
2005 1.788.000 2.24%
2006 4.326.000 58.67%
2007 5.275.000 17.99%
2008 1.886.000 -179.69%
2009 -3.096.000 160.92%
2010 4.644.000 166.67%
2011 10.293.000 54.88%
2012 3.624.000 -184.02%
2013 5.363.000 32.43%
2014 7.492.000 28.42%
2015 9.159.000 18.2%
2016 8.356.000 -9.61%
2017 6.579.000 -27.01%
2018 24.216.000 72.83%
2019 16.924.000 -43.09%
2020 7.234.000 -133.95%
2021 1.130.000 -540.18%
2022 -7.406.000 115.26%
2023 3.143.000 335.63%
2023 765.000 -310.85%
2024 782.000 2.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dr. Hönle AG Capital Expenditure
Year Capital Expenditure Growth
2002 1.694.000
2003 770.000 -120%
2004 355.000 -116.9%
2005 1.879.000 81.11%
2006 0 0%
2007 0 0%
2008 843.000 100%
2009 1.377.000 38.78%
2010 867.000 -58.82%
2011 1.583.000 45.23%
2012 2.232.000 29.08%
2013 2.659.000 16.06%
2014 3.085.000 13.81%
2015 2.136.000 -44.43%
2016 4.980.000 57.11%
2017 5.361.000 7.11%
2018 10.577.000 49.31%
2019 19.278.000 45.13%
2020 30.197.000 36.16%
2021 17.089.000 -76.7%
2022 4.309.000 -296.59%
2023 2.934.000 -46.86%
2023 448.000 -554.91%
2024 914.000 50.98%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dr. Hönle AG Equity
Year Equity Growth
2002 21.610.000
2003 23.584.000 8.37%
2004 24.647.000 4.31%
2005 26.564.000 7.22%
2006 26.710.000 0.55%
2007 28.326.000 5.71%
2008 30.579.000 7.37%
2009 25.624.000 -19.34%
2010 30.769.000 16.72%
2011 38.204.000 19.46%
2012 44.484.000 14.12%
2013 47.637.000 6.62%
2014 49.718.000 4.19%
2015 57.514.000 13.55%
2016 61.669.000 6.74%
2017 69.778.000 11.62%
2018 87.249.000 20.02%
2019 90.122.000 3.19%
2020 116.685.000 22.76%
2021 111.122.000 -5.01%
2022 107.238.000 -3.62%
2023 96.133.000 -11.55%
2023 99.801.000 3.68%
2024 93.582.000 -6.65%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dr. Hönle AG Assets
Year Assets Growth
2002 26.112.000
2003 28.331.000 7.83%
2004 29.502.000 3.97%
2005 32.080.000 8.04%
2006 32.333.000 0.78%
2007 34.521.000 6.34%
2008 48.514.000 28.84%
2009 38.527.000 -25.92%
2010 44.434.000 13.29%
2011 55.751.000 20.3%
2012 74.340.000 25.01%
2013 79.488.000 6.48%
2014 85.595.000 7.13%
2015 91.012.000 5.95%
2016 94.275.000 3.46%
2017 102.306.000 7.85%
2018 125.523.000 18.5%
2019 144.147.000 12.92%
2020 196.196.000 26.53%
2021 202.905.000 3.31%
2022 195.462.000 -3.81%
2023 176.156.000 -10.96%
2023 177.368.000 0.68%
2024 168.901.000 -5.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dr. Hönle AG Liabilities
Year Liabilities Growth
2002 4.331.000
2003 4.408.000 1.75%
2004 4.489.000 1.8%
2005 5.040.000 10.93%
2006 5.623.000 10.37%
2007 6.195.000 9.23%
2008 17.094.000 63.76%
2009 12.903.000 -32.48%
2010 13.665.000 5.58%
2011 17.547.000 22.12%
2012 29.856.000 41.23%
2013 31.851.000 6.26%
2014 35.877.000 11.22%
2015 33.498.000 -7.1%
2016 32.606.000 -2.74%
2017 32.528.000 -0.24%
2018 38.274.000 15.01%
2019 54.025.000 29.16%
2020 79.511.000 32.05%
2021 91.783.000 13.37%
2022 88.224.000 -4.03%
2023 80.023.000 -10.25%
2023 77.567.000 -3.17%
2024 75.260.000 -3.07%

Dr. Hönle AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
16.28
Net Income per Share
-0.89
Price to Earning Ratio
-13.05x
Price To Sales Ratio
0.71x
POCF Ratio
14.47
PFCF Ratio
28.28
Price to Book Ratio
0.75
EV to Sales
1.2
EV Over EBITDA
15.66
EV to Operating CashFlow
24.52
EV to FreeCashFlow
47.89
Earnings Yield
-0.08
FreeCashFlow Yield
0.04
Market Cap
0,07 Bil.
Enterprise Value
0,12 Bil.
Graham Number
17.53
Graham NetNet
-6.23

Income Statement Metrics

Net Income per Share
-0.89
Income Quality
-1.08
ROE
-0.06
Return On Assets
-0.03
Return On Capital Employed
-0.02
Net Income per EBT
1.13
EBT Per Ebit
1.77
Ebit per Revenue
-0.03
Effective Tax Rate
-0.14

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
-0.03
Pretax Profit Margin
-0.05
Net Profit Margin
-0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.02
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.8
Free CashFlow per Share
0.41
Capex to Operating CashFlow
0.49
Capex to Revenue
0.02
Capex to Depreciation
0.25
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.04
Days Sales Outstanding
65.77
Days Payables Outstanding
31.38
Days of Inventory on Hand
174.97
Receivables Turnover
5.55
Payables Turnover
11.63
Inventory Turnover
2.09
Capex per Share
0.39

Balance Sheet

Cash per Share
1,10
Book Value per Share
15,45
Tangible Book Value per Share
12.19
Shareholders Equity per Share
15.43
Interest Debt per Share
9.26
Debt to Equity
0.58
Debt to Assets
0.32
Net Debt to EBITDA
6.41
Current Ratio
1.98
Tangible Asset Value
0,07 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
123855000
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.12
Average Receivables
0,02 Bil.
Average Payables
0,01 Bil.
Average Inventory
35041500
Debt to Market Cap
0.77

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dr. Hönle AG Dividends
Year Dividends Growth
2002 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2011 0 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 2 100%
2021 1 0%
2022 0 0%

Dr. Hönle AG Profile

About Dr. Hönle AG

Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.

CEO
Dr. Markus Arendt
Employee
573
Address
Nicolaus-Otto-Str. 2
Munich, 82205

Dr. Hönle AG Executives & BODs

Dr. Hönle AG Executives & BODs
# Name Age
1 Peter Weinert
Head of Investor Relations
70
2 Dr. Markus Arendt
Chief Executive Officer, MD & Chairman of the Management Board
70

Dr. Hönle AG Competitors